Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 19Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 2Glioma 2Glioblastoma 2Brain Neoplasms 2Thromboembolism 1Solid Tumors 1Oligodendroglioma 1Neuroblastoma 1Lymphoma, Follicular 1Leukemia, Myeloid, Chronic-Phase 1Granulosa Cell Tumor 1Castration-resistant Prostate Cancer 1Breast Neoplasms 1Astrocytoma 1Advanced Cancer 1

Interventions

Cyclophosphamide 72fludarabine phosphate 64Peripheral Blood Stem Cell Transplantation 64Busulfan 50Cyclosporine 48Mycophenolic Acid 45Tacrolimus 41Antilymphocyte Serum 41Radiotherapy 37Whole-Body Irradiation 33Methotrexate 33Filgrastim 33Imatinib Mesylate 27Methylprednisolone 25Cord Blood Stem Cell Transplantation 24Melphalan 22Dasatinib 16sargramostim 15Etoposide 15nilotinib 14Cytarabine 14Interferon-alpha 13Therapeutics 11Flow Cytometry 11Cyclosporins 11Thiotepa 9Sirolimus 9Alemtuzumab 9Polymerase Chain Reaction 8Psychiatric Rehabilitation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Chronic-Phase × Ketoconazole × Clear all
NCT05638763 2022-12-06

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Hospital Universitario Dr. Jose E. Gonzalez

Phase 2 Unknown
15 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡